Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Brazilian Single-Center Initial Experience and Safety of Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Mariana Nassif Kerbauy, MD, PhD (she/her/hers)
Hematologist
Hospital Israelita Albert Einstein, Brazil